Clinical trial · Observational
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Multicenter Observational Prospective Study of Immune Checkpoint Inhibitors in Patients With Solid Neoplasms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- Three years
- description
- OS was defined as the time from the date of first administration of immunotherapy until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up.
Secondary outcomes (3)
- measure
- Progression Free Survival
- timeFrame
- Three years
- description
- PFS was measured from the date of first administration of immunotherapy to the date of disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 or death due to any cause, whichever occurred first. For patients whose disease did not progress, PFS was evaluated by censoring patients at their most recent imaging.
- measure
- Overall Objective Response Rate
- timeFrame
- At least 6 weeks after start of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age at least 18 years. * Pathologically confirmed diagnosis of a solid tumor cancer. * Patients receiving treatment with immune checkpoint inhibitors. * Ability to understand and willingness to provide the informed consent. Exclusion Criteria: * Age \< 18 years. * Patients with hematological malignancies or solid benign tumors. * Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.
References
Publications (1)
- DERIVEDDong H, Lan A, Gao J, An Y, Chu L, Yang X, Chu X, Hu J, Chu Q, Ni J, Zhu Z. Prognostic significance of bone metastasis and clinical value of bone radiotherapy in metastatic non-small cell lung cancer receiving PD-1/PD-L1 inhibitors: results from a multicenter, prospective, observational study. Transl Lung Cancer Res. 2024 Oct 31;13(10):2603-2616. doi: 10.21037/tlcr-24-441. Epub 2024 Oct 18. PMID 39507037